BLAINTRAVENOUSSOLUTION
Approved
Nov 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
15
Data completeness
3/8 — Basic
Drug data last refreshed 23h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Panzyga is an intravenous immunoglobulin (IVIG) derived from pooled human plasma that neutralizes antigens and modulates immune responses. It is indicated for primary immunodeficiency and other immune-mediated conditions requiring passive antibody replacement or immunomodulation. The product works by providing exogenous immunoglobulins to supplement or replace deficient endogenous antibody production.
$0.034BPart D
PeakPanzyga is in peak commercial stage with stable Part D market penetration, suggesting a mature brand team focused on market maintenance and optimization rather than rapid growth.
Mechanism of Action
Pharmacologic Class:
Antigen Neutralization
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (15)
Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections
Started Jun 2026
360 enrolled
HypogammaglobulinemiaAutoimmune ConditionsRheumatic Conditions+1 more
Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients
Started Oct 2023
30 enrolled
Pediatric Chronic Inflammatory Demyelinating Polyneuropathy
Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS)
Started Jun 2021
71 enrolled
Pediatric Acute-Onset Neuropsychiatric Syndrome
Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency
Started Dec 2020
24 enrolled
Primary Immune Deficiency
Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)
Started Oct 2020
247 enrolled
Chronic Lymphocytic LeukemiaHypogammaglobulinemia
Worked on Panzyga at Octapharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.